Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > New Cancer Treatment
View:
Post by xodcode on Sep 09, 2024 11:13am

New Cancer Treatment

Anyone watching SUMMIT (SMMT) today: up 50% plus last time I checked. Results beat Keytruda!
Comment by DeathXray33 on Sep 09, 2024 11:32am
"Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab" ------------------------- Meaningful Benefit ??? Hmm... ;-)---------- @ > 1.532 million now.
Comment by N0taP00p on Sep 09, 2024 11:39am
Had been watching it but didn't pull the trigger.  They have big US VCs backing them. If TLT were in the US, would probably be sitting at 5 bucks easy, with the kind of data they have.  Of course, the VCs would push much harder for results too.  Maybe we finally get a big jump like SMMT in early October.
Comment by riverrrow on Sep 09, 2024 1:08pm
It was certainly my dream for TLT to be trading at $5 while I owned over a million tradeable warrants. Sad sigh.
Comment by DeathXray33 on Sep 11, 2024 3:38pm
I just reread that news release; it makes no sense. Can anyone decipher it? "Meaningful benefit" , "Manageable safety", "Reduce the risk of" ? 16.64 Billion MC ? --------------------- It seems to be written in the Slickconian language. An ancient Demon language used to deceive. Only a few here can decipher the Slickconian language.
Comment by O12009 on Sep 11, 2024 4:11pm
The trial was done in China with no peer review very few results to go by. That treatment is a long way off as they will need to do a trial with FDA approval and be recognized by the majority of the free world.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250